Target Name: GIMAP2
NCBI ID: G26157
Other Name(s): IAN12 | GTPase, IMAP family member 2 | GTPase IMAP family member 2 | immune-associated nucleotide-binding protein 12 | Immunity associated protein 2 | DKFZp586D0824 | IMAP2 | immunity associated protein 2 | MGC24275 | OTTHUMP00000212217 | HIMAP2 | GIMA2_HUMAN | Immunity-associated protein 2 | hIMAP2

GIMAP2: A Potential Drug Target for Psychiatric Disorders

GIMAP2 (Gimap2) is a protein that is expressed in various tissues and cells in the human body. It is a member of the G protein-coupled receptor (GPCR) family, which is a large family of transmembrane proteins that play a critical role in cellular signaling. GIMAP2 is known for its role in the regulation of neurotransmitter signaling, particularly in the brain.

Recent studies have suggested that GIMAP2 may be a drug target or biomarker for various psychiatric and neurological disorders, including depression, anxiety, and neurodegenerative diseases. This is because GIMAP2 has been shown to play a role in the regulation of neurotransmitter signaling in the brain, and disruptions in this signaling can lead to the development of these disorders.

One of the key mechanisms by which GIMAP2 is involved in neurotransmitter signaling is through its role as a negative regulator of the neurotransmitter GABA. GABA is a well-known inhibitory neurotransmitter that plays a critical role in the regulation of neural activity and is involved in a wide range of physiological processes, including sleep, wakefulness, and anxiety.

GIMAP2 is known to interact with GABA receptors and prevent them from functioning properly. This interaction between GIMAP2 and GABA receptors is important for the regulation of neurotransmitter signaling because GABA is a potent inhibitor of neurotransmitter signaling. When GABA is inhibited, neurotransmitters can become overactive and lead to the development of hyperactivity or anxiety.

In addition to its role in GABA signaling, GIMAP2 has also been shown to play a role in the regulation of other neurotransmitters, including dopamine and serotonin. GIMAP2 has been shown to interact with dopamine receptors and prevent them from functioning properly, which is important for the regulation of motivation and pleasure. Similarly, GIMAP2 has been shown to interact with serotonin receptors and prevent them from functioning properly, which is important for the regulation of mood and anxiety.

GIMAP2's role in neurotransmitter signaling is also important for the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. These conditions are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles, which are thought to be the hallmark of these diseases.

Recent studies have suggested that disruptions in GIMAP2 signaling may contribute to the development and progression of neurodegenerative diseases. For example, studies have shown that mice that have been genetically modified to disrupt GIMAP2 signaling have exhibited increased neurodegeneration and cognitive impairments, suggesting that GIMAP2 may play a protective role in the development of these conditions.

In addition to its potential as a drug target or biomarker, GIMAP2 is also of interest as a potential therapeutic approach for the treatment of psychiatric and neurological disorders. For example, studies have shown that GIMAP2 blockers can alleviate symptoms of anxiety and depression in animal models of these conditions. This suggests that GIMAP2 may be an effective therapeutic approach for the treatment of psychiatric and neurological disorders.

In conclusion, GIMAP2 is a protein that is expressed in various tissues and cells in the human body and is known for its role in the regulation of neurotransmitter signaling. Recent studies have suggested that GIMAP2 may be a drug target or biomarker for various psychiatric and neurological disorders, including depression, anxiety, and neurodegenerative diseases. Its role in GABA signaling and its interaction with other neurotransmitters make GIMAP2 an important target for the development of new therapeutic approaches for the treatment of psychiatric and neurological disorders.

Protein Name: GTPase, IMAP Family Member 2

Functions: The heterodimer formed by GIMAP2 and GIMAP7 has GTPase activity. In contrast, GIMAP2 has no GTPase activity by itself

More Common Targets

GIMAP3P | GIMAP4 | GIMAP5 | GIMAP6 | GIMAP7 | GIMAP8 | GIMD1 | GIN1 | GINM1 | GINS complex | GINS1 | GINS2 | GINS3 | GINS4 | GIP | GIPC1 | GIPC2 | GIPC3 | GIPR | GIT1 | GIT2 | GJA1 | GJA10 | GJA1P1 | GJA3 | GJA4 | GJA5 | GJA8 | GJA9 | GJA9-MYCBP | GJB1 | GJB2 | GJB3 | GJB4 | GJB5 | GJB6 | GJB7 | GJC1 | GJC2 | GJC3 | GJD2 | GJD3 | GJD4 | GK | GK2 | GK3 | GK5 | GKAP1 | GKN1 | GKN2 | GKN3P | GLA | GLB1 | GLB1L | GLB1L2 | GLB1L3 | GLC1C | GLCCI1 | GLCCI1-DT | GLCE | GLDC | GLDN | GLE1 | GLG1 | GLI1 | GLI2 | GLI3 | GLI4 | GLIDR | GLIPR1 | GLIPR1L1 | GLIPR1L2 | GLIPR2 | GLIS1 | GLIS2 | GLIS3 | GLIS3-AS1 | GLMN | GLMP | GLO1 | GLOD4 | GLOD5 | GLP1R | GLP2R | GLRA1 | GLRA2 | GLRA3 | GLRA4 | GLRB | GLRX | GLRX2 | GLRX3 | GLRX3P2 | GLRX5 | GLS | GLS2 | GLT1D1 | GLT6D1 | GLT8D1 | GLT8D2